Preimplantation genetic diagnosis (PGD) is an in-vitro fertilization procedure in which one or few cells are biopsied from an embryo before implantation and tested for genetic defects. PGD helps to identify genetic defects in embryos developed through IVF and assists in selective implantation of healthy embryos. It aids in preventing the transmission of hereditary disorders to offspring and allows couples to choose only embryos without genetic conditions. Factors such as rising infertility rates, increasing risk of chromosomal abnormalities with advancing maternal age, growing focus on prevention of genetic disorders, and technological advancements in PGD techniques can drive the global preimplantation genetic diagnosis market growth during the forecast period.

Market Dynamics:

Global preimplantation genetic diagnosis market growth is driven by rising infertility rates, growing focus on prevention of genetic disorders, increasing maternal age globally that leads to higher chances of chromosomal abnormalities. However, limitations of PGD, social and ethical concerns regarding PGD, and stringent regulations can hamper the market growth. Various initiatives by government and private organizations to spread awareness about PGD can offer lucrative market growth opportunities. Market players are focusing on new techniques such as next-generation sequencing to provide comprehensive chromosome screening with improved outcomes.

Key Features of the Study:

• This report provides in-depth analysis of the global preimplantation genetic diagnosis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global preimplantation genetic diagnosis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include CooperSurgical, Illumina, Thermo Fisher, Agilent Technologies, PerkinElmer, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global preimplantation genetic diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preimplantation genetic diagnosis market

Detailed Segmentation-

• By Type:
• • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others
• By End User
• • Diagnostic Laboratories
  • Hospitals
  • Clinics
  • Others
• By Region:         
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
• • PerkinElmer, Inc.
  • Genea Limited
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Illumina, Inc.
  • CooperSurgical, Inc.
  • Beijing Genomics Institute (BGI)
  • LabCorp of America Holdings (Laboratory Corporation of America)
  • Natera, Inc.
  • Oxford Gene Technology
  • California Pacific Medical Center
  • Good Start Genetics, Inc.
  • Invitae Corporation
  • F. Hoffmann-La Roche AG
  • Progenesis